Zobrazeno 1 - 10
of 172
pro vyhledávání: '"Toshihide, Yokoyama"'
Autor:
Kenji Morimoto, Ryosuke Hamashima, Tadaaki Yamada, Toshihide Yokoyama, Takehiko Kobayashi, Kazunari Tsuyuguchi, Takanori Kanematsu, Nobuyo Tamiya, Taisuke Tsuji, Ryota Nakamura, Yuki Katayama, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama
Publikováno v:
Thoracic Cancer, Vol 15, Iss 26, Pp 1882-1888 (2024)
Abstract Background Advances in anticancer drugs for lung cancer (LC) have improved the prognosis of LC. Chronic pulmonary aspergillosis (CPA) is a progressive and often exacerbating respiratory disease with a poor prognosis. To date, the prognosis o
Externí odkaz:
https://doaj.org/article/5e4e9f8c9c6e43e9ab22bede456c8be8
Autor:
Satoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, Kyoichi Okishio, Morihito Okada, Ichiro Yoshino, Jiro Okami, Kazuhisa Takahashi, Norihiko Ikeda, Masayuki Tanahashi, Yuichi Tambo, Haruhiro Saito, Shinichi Toyooka, Hidetoshi Inokawa, Toyofumi Chen‐Yoshikawa, Toshihide Yokoyama, Tatsuro Okamoto, Noriko Yanagitani, Masahide Oki, Makoto Takahama, Kenji Sawa, Hirohito Tada, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Kazuto Nishio
Publikováno v:
Molecular Oncology, Vol 18, Iss 2, Pp 305-316 (2024)
The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC). Although the primary endpo
Externí odkaz:
https://doaj.org/article/5ef9670861fa45fda1c2e13f031a8170
Publikováno v:
Respirology Case Reports, Vol 12, Iss 5, Pp n/a-n/a (2024)
Key message Tepotinib may cause hand‐foot skin reactions with keratotic changes. When such changes are observed in the hands or toes after starting tepotinib treatment, its side effects should be considered, and corticosteroid ointment or withdrawa
Externí odkaz:
https://doaj.org/article/7bba13ee29b7409abd87350e496fb2b9
Autor:
Hiroaki Kanemura, MD, MPH, PhD, Toshihide Yokoyama, MD, Ryu Nakajima, MD, PhD, Atsushi Nakamura, MD, PhD, Hiroaki Kuroda, MD, PhD, Yoshitaka Kitamura, MD, PhD, Hiroyasu Shoda, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihiro Miyata, MD, PhD, Tatsuro Okamoto, MD, PhD, Kyoichi Okishio, MD, PhD, Masahide Oki, MD, PhD, Yuichi Sakairi, MD, PhD, Toyofumi Fengshi Chen-Yoshikawa, MD, PhD, Tadashi Aoki, MD, Tatsuo Ohira, MD, PhD, Isao Matsumoto, MD, PhD, Kiyonobu Ueno, MD, PhD, Takuro Miyazaki, MD, PhD, Haruhisa Matsuguma, MD, PhD, Hideoki Yokouchi, MD, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Isamu Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100658- (2024)
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence
Externí odkaz:
https://doaj.org/article/6165423210284cf69a0cf2aac07b491b
Autor:
Takehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, Shunsuke Teraoka, Hiroshi Kobe, Koichi Azuma, Teppei Yamaguchi, Takeshi Masuda, Toshihide Yokoyama, Kohei Otsubo, Koji Haratani, Daisuke Hayakawa, Masahide Oki, Shinnosuke Takemoto, Tomohiro Ozaki, Yusaku Akashi, Akito Hata, Hiroya Hashimoto, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21097-21110 (2023)
Abstract Background Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non‐small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing for EGF
Externí odkaz:
https://doaj.org/article/653a72701e5d487b855668fed38c1519
Autor:
Kazushige Wakuda, Hirotsugu Kenmotsu, Yuki Sato, Atsushi Nakamura, Hiroaki Akamatsu, Motoko Tachihara, Satoru Miura, Toshihide Yokoyama, Keita Mori, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background The ALTA-1L study compared brigatinib with crizotinib in untreated ALK-rearranged non-small cell lung cancer (NSCLC) patients, demonstrating the efficacy of brigatinib. Although the median progression-free survival (PFS) of brigat
Externí odkaz:
https://doaj.org/article/d9026cc985de4542a52c71143cb58729
Autor:
Hirotaka Matsumoto, Hiroaki Akamatsu, Nobuyuki Yamamoto, Yuki Sato, Daichi Fujimoto, Yoshihiko Taniguchi, Motohiro Tamiya, Yasuhiro Koh, Junya Fukuoka, Hisashi Tanaka, Naoki Furuya, Ryota Shibaki, Tsukasa Nozawa, Akira Sano, Yuka Kitamura, Takashi Kijima, Toshihide Yokoyama, Satoru Miura, Akito Hata, Jun Sugisaka
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background In small-cell lung cancer (SCLC), the tumor immune microenvironment (TIME) could be a promising biomarker for immunotherapy, but objectively evaluating TIME remains challenging. Hence, we aimed to develop a predictive biomarker of immunoth
Externí odkaz:
https://doaj.org/article/6255e060953c4901b89e6055b35b9eff
Autor:
Tae Hata, Chikara Sakaguchi, Keita Hirano, Hiroshi Kobe, Masaki Ishida, Takayuki Nakano, Yusuke Tachibana, Nobuyo Tamiya, Shinsuke Shiotsu, Takayuki Takeda, Tadaaki Yamada, Toshihide Yokoyama, Michiko Tsuchiya, Yukio Nagasaka
Publikováno v:
Thoracic Cancer, Vol 14, Iss 11, Pp 1004-1011 (2023)
Abstract Background Patients with epidermal growth factor receptor (EGFR)‐mutated, advanced non–small cell lung cancer have received immunochemotherapy as one of the treatment options after tyrosine kinase inhibitor (TKI) failure. Methods We retr
Externí odkaz:
https://doaj.org/article/4d514c461e6642988de42d18d2872f6d
Autor:
Kazushige Wakuda, MD, Hiroyuki Yamaguchi, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Minoru Fukuda, MD, PhD, Kentaro Ito, MD, Yuko Tsuchiya-Kawano, MD, PhD, Kentaro Tanaka, MD, PhD, Taishi Harada, MD, PhD, Yuki Nakatani, MD, Satoru Miura, MD, Toshihide Yokoyama, MD, Tomomi Nakamura, MD, Miiru Izumi, MD, PhD, Atsushi Nakamura, MD, PhD, Satoshi Ikeda, MD, PhD, Koichi Takayama, MD, PhD, Kenichi Yoshimura, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kenji Sugio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100587- (2023)
Introduction: Osimertinib may be effective in treating central nervous system (CNS) metastasis, but its efficacy in treating radiation therapy (RT)-naive metastasis is unclear. The OCEAN study assessed the efficacy of osimertinib against RT-naive CNS
Externí odkaz:
https://doaj.org/article/2430d3ab5e8943f5b2079f35a13f2fad
Autor:
Junko Tanizaki, MD, PhD, Hiroaki Kuroda, MD, PhD, Toshihide Yokoyama, MD, Makoto Takahama, MD, PhD, Hiroyasu Shoda, MD, PhD, Atsushi Nakamura, MD, PhD, Yoshitaka Kitamura, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihisa Kadota, MD, PhD, Kenji Sawa, MD, PhD, Kyoichi Okishio, MD, PhD, Morihito Okada, MD, PhD, Chihiro Suminaka, MS, Kenta Noda, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Kenji Chamoto, PhD, Tasuku Honjo, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100590- (2023)
Introduction: Perioperative treatment in NSCLC has gained marked attention with the introduction of immune checkpoint inhibitors. Such a paradigm shift has given us additional opportunities to evaluate potential biomarkers in patients with these cura
Externí odkaz:
https://doaj.org/article/3f386ee3f72d427a96a00d99cb19bacc